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4:00 p.m. 
833-1 Randomized Trial of Cholesterol-Lowering, and of 
Antioxidant Vitamins, in 6,000 People With Diabetes 
Mellitus 
Rory Collins, Jane Armitaoe, Sarah Parish, Peter Sleight, Richard Peto, for the MRC/ 
BHF Heart Protection Study Collaborative Group, Clinical Trial Service Unit, Oxford 
University Oxford, United Kingdom. 
Background: People with diabetes mellitus (DM) are at increased risk of coronary heart 
disease (CHD). Previous primary prevention trials have involved too few people with DM 
to assess reliably the effects of cholesterol-lowering, and of antioxidant vitamins, on CHD 
risk. 
Methods: A wide range of people at increased risk of CHD were randomly allocated to 
receive 40 mg simvastatin daily, or matching placebo tablets, for an average of at least 
five years. In addition, using a factorial design, half of the patients were randomly allo- 
cated active antioxidant vitamins (600 mg E, 250 mg C, 20 mg beta-carotene daily) and 
half allocated placebo vitamin capsules. 
Results: Between July 1994 and May 1997, 5,963 people aged 40-80 years with DM 
were recruited (along with a further 14,573 high-risk patients without diagnosed DM). By 
predefined criteria, 615 were classified as type 1 DM and 5,348 as type 2 DM. Some his- 
tory of CHD was reported at study entry by 1,978 of these DM patients, but 3,985 did not. 
Allocation to 40 mg daily simvastatin has produced average reductions during the study 
of about 45 mg/dl in LDL-cholestarol and 35 mg/dl in triglycerides. Among the DM 
patients without pre-existing CHD, about 300 CHD events are expected before sched- 
uled follow-up is completed in October 2001. 
Conclusion: This study will provide the first large-scale prospective vidence as to 
whether reducing LDL cholesterol, and supplementing antioxidant vitamins, produces 
worthwhile benefits in a wide range of DM patients. 
4:15 p.m. 
833-2 Randomized Trial of Cholesterol-Lowering and 
Antioxidant Vitamins in 7,000 High-Risk Individuals 
With LDL Cholesterol Below 120 mg/dl 
Rorv Collins. Jane Armitage, Sarah Parish, Peter Sleight, Richard Peto, for the MRC/ 
BHF Heart Protection Study Collaborative Group, Clinical Trial Service Unit, University of 
Oxford, Oxford, United Kingdom. 
Background: It has been suggested that lowering LDL-cholesterol levels below about 
120 mg/dl does not reduce coronary heart disease (CHD) dsk. 
Methods: A wide range of people at increased risk of CHD were randomly allocated to 
receive 40 mg simvastatin daily, or matching placebo tablets, for an average of at least 
five years. In addition, using a factorial design, half of the patients were randomly allo- 
cated active antioxidant vitamins (600 mg E, 250 mg C, 20 mg beta-carotane daily) and 
haft allocated placebo vitamin capsules. Results: Between July 1994 and May 1997, 
20,536 people aged 40-80 years were recruited. Blood LDL-cholesterol levels at entry 
were below 3.0 mmol/I (115 mg/dl) in 6,793 randomised patients, ->3<9.5 mmol/I in 5,063, 
and ->3.5 mmoUI (135 mg/dl) in 8,680. Previous myocardial infarction was reported at 
entry by 8,510 patients (most of whom had "low" blood cholesterol or were elderly or 
female), 4,869 had some other history of CHD, and 7,157 without CHD had other occlu- 
sive vascular disease or diabetes mellitus. Allocation to 40 mg daily simvastatin has pro- 
duced average reductions during the study of about 45 mg/dl in LDL-cholesterol. About 
2,500 CHD events and 1,000-1,500 CHD deaths are expected before scheduled follow- 
up is completed in October 2001. Conclusion: This study will provide the first large- 
scale prospective vidence as to whether educing LDL-cholesterol, and supplementing 
antioxidant vitamins, produces worthwhile benefits in people who, despite relatively low 
LDL-cholesterol levels, are still at increased risk of CHD events. 
4:30 p.m. 
833-3 Randomized Trial of Cholesterol-Lowering and 
Antioxidant Vitamins in 5,000 Women at High-Risk of 
Coronary Heart Disease 
Rory Collins, Jane Armitage, Sarah Parish, Peter Sleioht, Richard Peto, for the MRC/ 
BHF Heart Protection Study Collaborative Group, Clinical Trial Service Unit, Oxford 
University, Oxford, United Kingdom. 
Background: Previous trials have involved too few women to provide reliable direct evi- 
dence about the effects of cholesterol-lowering, and of antioxidant vitamins, on coronary 
heart disease (CHD) risk in females. 
Methods: A wide range of people at increased risk of CHD were randomly allocated to 
receive 40 mg simvastatin daily, or matching placebo tablets, for an average of at least 
five years. In addition, using a factorial design, half of the patients were randomly allo- 
cated active antioxidant vitamins (600 mg E, 250 mg C, 20 mg beta-carotene daily) and 
half allocated placebo vitamin capsules. 
Reeults: Between July 1994 and May 1997, 5,082 women and 15, 454 men aged 40-80 
years were recruited. Previous myocardial infarction was reported at study entry by 8,510 
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1000/40 A 10mg S 10mg 1000/40 A 20mg S 20mg 
Week 8 Week 12 
LDL-C -39%* -38% -28% -42%* -45% -35% 
HDL-C 20%** 3% 7% 19%** 3% 8% 
Triglyceride -30%** -15% -10% -32%** -23% -6% 
Lipoprotein (a) o16%** 5% -1% -20%** 3% -1% 
*P<0.001 versus S; **P<0.001 versus A and S 
patients (most of whom were female, elderly or with "low" blood cholesterol), 4,869 had 
some other history of CHD, and 7,157 without CHD had other occlusive vascular disease 
or diabetes melUtus. Allocation to 40 mg daily simvastatin has produced average reduc- 
tions during the study of about 45 mg/dl in LDL-cholestarol. About 2,500 CHD events and 
1,000-1,500 CHD deaths are expected before scheduled follow-up is completed in Octo- 
ber 2001. 
Conclusion: This study will provide the first large-scale prospective vidence as to 
whether reducing LDL cholesterol, and supplementing antioxidant vitamins, produces 
worthwhile benefits in women at increased risk of CHD events. 
4:45 p.m. 
833-4 EzeUmibe Added to Ongoing Statin Therapy for 
Treatment of Primary Hypercholesterolemia 
Harold Bavs, Stuart Weiss, Claude Gagne, Pedro Mata, Barry Gombiner, Michael 
Melino, Kathedne Quinto, Meehyung Cho, Merck/Shedng-P/ough Pharmaceuticals, 
North Wales, Pennsylvania. 
Background: A large percentage of statin-traated patients have LDL-C concentrations 
above NCEP goals. This randomized, double-blind, placebo-controlled study evaluated 
the efficacy and safety of adding ezetimibe (EZE) to on-going statin therapy in patients 
with hypemholesterolemia, CHD, or multiple risk factors who required further LDL-C low- 
ering. 
Methods: Patients (n=769) on a stable dose of statins for > 6 wk were randomized to 
placebo (PBO) or EZE 10 mg/d in addition to their open-label statins for 8 wk. The pri- 
mary efficacy variable was % change from baseline to endpoint in LDL-C. Secondary 
variables included HDL-C and triglycerides (TG). 
Results: Baseline LDL-C concentrations were 138.8 mg/dl for Statin + PBO vs. 138.2 
mg/dl for Statin + EZE. The table shows mean % changes for LDL-C and secondary vari- 
ables. 
Treatment LDL-C HDL-C TG 
Statin + PBO (n=390) -3.7_+0.7 1.0±0.5 -2.9_+1.5 
Statin + EZE (n=379) -25.1_+0.7"** 2.7-+0.5* -14.0_+1.4"* 
*p<0.05, **p<0.01, and ***p<9.001 versus Statin + PBO 
Compared with placebo, addition of EZE to on-going statin therapy led to mean changes 
of -21.5%, +1.7%, and -11.4% for LDL-C, HDL-C and TG, respectively. Among patients 
not at their NCEP LDL-C goal at baseline, 18.9% on Statin + PBO vs. 71.5% on Statin + 
EZE reached their goal at endpoint (p<0.001). EZE + Statin was well tolerated, and had a 
safety profile similar to Statin alone. 
Conclusion: Addition of EZE to on-going statin therapy led to significant improvements 
in LDL-C, HDL-C, and TG, and facilitated attainment of NCEP LDL-C goals, thus offering 
a potential new therapeutic option for patients on statins requiring further LDL-C reduc- 
tions. 
5:00 p.m. 
833-5 Lipoprotein Effects of a New Dual Component Drug 
(Extended-Release Niacin/I.ovastatin) Compared to 
Starting Doses of Atorvastatin and Simvastatin 
Harold E. Bavs. Mark E. McGovern, Phillip D. Simmons, Louisville Metabolic and 
Atherosclerosis Research Center, Louisville, Kentucky. 
Background: Global improvements in lipoprotein levels may best reduce atherosclerosis 
progression and clinical events. This study compared a new dual component, single tab- 
let lipoprotein modifier (niacin extended-rslease/Iovastatin [ERNL]) to atorvastatin (A) 
and simvastatin (S), including their starting doses (A = 10 mg, S = 20 mg). Methods: This 
was a randomized, open-label, multicenter study in 316 men and women 18 - 70 years 
old who were randomized to ERNL, A, or S. ERNL was titratad at 4 week intervals, from 
500/20 (milligrams niacin extended-release/milligrams Iovastatin) to 1000/40 initially. 
One half of the 1000/40 treated subjects were then titratad to 1500/40, and then to 2000/ 
40. A and S were also titratad from 10 mg to 20 mg and then to 40 mg. Results: Baseline 
mean values for all subjects were, for LDL-C 191 mg/dL, HDL-C 38 mg/dL, triglycarides 
175 mg/dL, Upoprotain (a) 36 mg/dL, and they did not significantly differ between groups. 
Lipid effects at typical starting doses of all 3 drugs are shown in the Table. Flushing 
caused 7% of patients to withdraw from ERNL. No myopathy was observed. Mean ala- 
nine aminotransferase l vels were significantly higher with A than with ERNL or S at all 
study visits. Conclusions: At typical starting doses, ERNL reduces LDL-C comparably to 
A and more than S. ERNL significantly increases HDL-C and significantly lowers both 
triglycerides and lipoprotein (a) more than A or S, and thus results in a greater global 
improvement inlipoprotein blood levels. 
Percent Change From Baseline 
